Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Weber

Showing results (161-170 of 341) with videos related to

Pageof 35
Sort By:
Journal of Clinical Hypertension (Greenwich, Conn.)|October 18, 2005
Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patientsGeorge L Bakris, David Hg Smith, Thomas D Giles, et al.
Hypertension (Dallas, Tex. : 1979)|February 2, 2011
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertensionWilliam B White, Michael A Weber, Domenic Sica, et al.
Blood Pressure Monitoring|January 22, 2014
Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertensionMichael A Weber, William B White, Domenic Sica, et al.
American Journal of Therapeutics|July 1, 1996
Combination Treatment with Sustained-Release Verapamil and Indapamide in the Treatment of Mild-to-Moderate HypertensionStanley S. Franklin, Matthew R. Weir, David H.G. Smith, et al.
Lancet (London, England)|June 3, 2014
Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre studyThomas D Giles, Michael A Weber, Jan Basile, et al.
Hypertension (Dallas, Tex. : 1979)|April 19, 2003
Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertensionWilliam B White, Daniel Duprez, Richard St Hillaire, et al.
Circulation. Cardiovascular Quality and Outcomes|December 9, 2022
Patient Preferences for Pharmaceutical and Device-Based Treatments for Uncontrolled Hypertension: Discrete Choice ExperimentDavid E Kandzari, Michael A Weber, Christine Poulos, et al.
The American Journal of Cardiology|September 16, 2018
Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic HypertensionKeith C Ferdinand, George L Bakris, William C Cushman, et al.
Journal of Hypertension|November 6, 2025
Effects of aprocitentan on prognostically relevant ambulatory blood pressure-derived variables in resistant hypertensionMarkus P Schlaich, Michael A Weber, John M Flack, et al.
American Journal of Hypertension|November 20, 2020
Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant HypertensionRobert D Brook, Niko Kaciroti, George Bakris, et al.
Pageof 35

Showing results (161-170 of 341) with videos related to

Sort By:
Pageof 35
Journal of Clinical Hypertension (Greenwich, Conn.)|October 18, 2005
Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patientsGeorge L Bakris, David Hg Smith, Thomas D Giles, et al.
Hypertension (Dallas, Tex. : 1979)|February 2, 2011
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertensionWilliam B White, Michael A Weber, Domenic Sica, et al.
Blood Pressure Monitoring|January 22, 2014
Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertensionMichael A Weber, William B White, Domenic Sica, et al.
American Journal of Therapeutics|July 1, 1996
Combination Treatment with Sustained-Release Verapamil and Indapamide in the Treatment of Mild-to-Moderate HypertensionStanley S. Franklin, Matthew R. Weir, David H.G. Smith, et al.
Lancet (London, England)|June 3, 2014
Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre studyThomas D Giles, Michael A Weber, Jan Basile, et al.
Hypertension (Dallas, Tex. : 1979)|April 19, 2003
Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertensionWilliam B White, Daniel Duprez, Richard St Hillaire, et al.
Circulation. Cardiovascular Quality and Outcomes|December 9, 2022
Patient Preferences for Pharmaceutical and Device-Based Treatments for Uncontrolled Hypertension: Discrete Choice ExperimentDavid E Kandzari, Michael A Weber, Christine Poulos, et al.
The American Journal of Cardiology|September 16, 2018
Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic HypertensionKeith C Ferdinand, George L Bakris, William C Cushman, et al.
Journal of Hypertension|November 6, 2025
Effects of aprocitentan on prognostically relevant ambulatory blood pressure-derived variables in resistant hypertensionMarkus P Schlaich, Michael A Weber, John M Flack, et al.
American Journal of Hypertension|November 20, 2020
Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant HypertensionRobert D Brook, Niko Kaciroti, George Bakris, et al.
Pageof 35